Immunoglobulin response to intravenous streptokinase in acute myocardial infarction SIR,-Lynch et al's study (British Heart Journal 1991; 66:139-42) contributes to the growing body of information on the immune response after administration of intravenous streptokinase for acute myocardial infarction. The current focus has been on the length of the period during which important titres of antibodies to and neutralising capacity for streptokinase persist (these do not always correlate precisely2). Studies by Lynch et al ' and Jalilal and Morris3 showed that this period extends at least to 12 months, and further work is awaited to determine the outer limit of this period. During this period streptokinase should not be readministered because of fears of an anaphylactic reaction and also that the drug will be neutralised and hence ineffective.
The current recommendations ofthe 1990-91 Data Sheet Compendium are that a second dose of streptokinase should not be given within a period offive days to six months after the first. A recent Drug and Therapeutics Bulletin states that this will soon be amended to a 12 month interval.4 Recent authoritative papers5 6 have been broader in their recommendations, suggesting that streptokinase and anistreplase should not be readministered within a year, and the latter paper6 concluded with the assertion that tissue plasminogen activator (alteplase) should be used if repeat thrombolysis is required (no time limit was stated so it presumably extended indefinitely from day 0). A policy of not repeating streptokinase for a year from day 0 has been widely adopted. These conclusions are important because alteplase costs ten times as much as streptokinase.
This policy loses sight of the early window that exists before the development of a significant immune response to streptokinase. This is a worthwhile opportunity given that 9% of patients will reinfarct in the first year after thrombolysis.7 In a substantial number of these patients reinfarction requiring repeat thrombolysis occurs in the first few days after thrombolysis. In White et al's 1990 study of repeat thrombolysis after myocardial infarction 31 patients were treated for recurrent myocardial infarction after thrombolysis between one and 716 days after initial thrombolysis.' The median interval was only five days and 10 ofthe 31 patients were treated in the first three days. Lynch et al's study shows that antibody titres to streptokinase (IgG) do not rise above baseline until day four, suggesting that a significant immune response (either anaphylactic or neutralising) is unlikely before this. The work of Massel et al on neutralising antibody showed a neutralising capacity equivalent to 1 5 x 106 units streptokinase between days five and nine in all their patients8 (this small study (11 patients) may not have adequately defined the normal range). This again suggests that there is an early opportunity to readminister streptokinase safely and effectively. Indeed though White et al recommended that streptokinase should not be readministered within a year they did show that readministration within this period was effective (albeit with an increased incidence of minor side effects).
This evidence suggests that streptokinase can be readministered safely and effectively from 0 to 3 days after the initial event. A further large study of neutralising capacity would be helpful because the most recent study dealt only with antibody response and a previous study of neutralising capacity was small. If this policy is adopted as a refinement of the day 0 to one year policy, which seems to be emerging, it is likely to have an impact on coronary care unit drug bills. antigen, streptokinase. Subsequently, there is a gradual rise in antibody titre, which does not become significantly higher than baseline titres until day 4. During this time window of 0-3 days, when antibody titres are no higher than pretreatment titres, it is probably as safe and effective to re-administer streptokinase in the event of a repeat infarction as in the case of the initial infarct.
We are continuing to monitor streptokinase antibody titres in this cohort of 20 patients, who have now reached the 18 month time point. Though they are gradually declining, the mean (SD) IgG titres to streptokinase are still significantly raised at two years (86-42 (102 9)) over baseline titres (14 63 (4) (p < 0 025). Repeat infarction after 72 hours and until at least 18 months after the initial infarct should probably be managed with a non-streptokinase thrombolytic agent until the significance of these antibodies is known. This letter was shown to the authors who reply asfollows:
SIR,-We thank Hall and Ferro for their interesting comments on our paper. The mechanism ofour observation that adrenaline produced ischaemia at a lower rate-pressure product than exercise must remain speculative, but we agree that the mechanism proposed by Hall and Ferro is also consistent with our data. It is interesting to consider the ideal properties for a fi blocker in the setting of acute myocardial infarction. The beta-i selective agent atenolol was shown in ISIS-' to reduce mortality when used early in acute myocardial infarction, a benefit largely due to a decrease in cardiac rupture. No other f blocker has been shown to decrease mortality when given acutely. But both propranolol2 and metoprolol' have been shown to reduce ventricular fibrillation in acute myocardial infarction. In animal studies timolol, pindolol, propranolol, metoprolol, and labetalol all increased the ventricular fibrillation threshold to a similar extent.4 Adrenaline is unlikely to be of direct relevance in causing late mortality after acute myocardial infarction but the question of which # blocker to use orally after acute myocardial infarction is as important as the question of which # blocker to use acutely.
Propranolol, timolol, and metoprolol are all reported to reduce mortality and particularly sudden death after acute infarction.5 The mechanisms of benefit may be many and are probably different from those when f blockers are used acutely.6 It may be that here lipid solubility is more important than f-1 selectivity. An overview ofthe long-term fP blocker trials has not suggested any difference between the fl-I selective and non-selective # blockers,7 though it seems that f blockers that do not have partial agonist activity may be more effective than those that do. There are insufficient data to be certain whether lipid solubility is important in this respect but all the drugs known to be efficacious are lipid soluble. Given the uncertainty about the importance of the ancillary properties of f blockers it seems reasonable to suggest that only P blockers with proven effects should be used for postinfarction prophylaxis' and, de- spite the theoretical advantages of non-selective fi blockade advanced by Hall and To assess the effect of cyclosporin in vitro, O'Neil et al applied the protocol that we have previously described.2 After three hours of incubation with cyclosporin, the maximal relaxation (mean (SEM)) to substance P was reduced from 76-6 (7 4)% in control coronary artery rings to 630 (11i-5)% and 62-2 (II-1)% in rings pretreated with cyclosporin 1000 and 2000 ng/ml, respectively. This difference was not statistically significant. However, at lower concentrations (10-'°and 10-9 mol/l) of substance P, the relaxant responses were significantly reduced in coronary artery rings incubated with cyclosporin compared with control rings (shown by O'Neil et al in fig 1) . 
